. 2017 Sep 6;8:607. doi: 10.3389/fphar.2017.00607
Copyright © 2017 Scavone, Sportiello, Sullo, Ferrajolo, Ruggiero, Sessa, Berrino, di Mauro, Berrino, Rossi, Rafaniello, Capuano and BIO-Cam Group.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Figure 2.
(A,B) Adverse events distribution by biotech drugs and follow-up categories.